Citable filing context
DGX's research view summarizes recent SEC filing context, starting with earnings from Jul 23, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 23, 2026 | earnings | Quest Diagnostics reported Q2 2026 revenue of $3.04 billion and raised its full-year 2026 revenue and EPS guidance. |
| May 21, 2026 | other | Quest Diagnostics announced voting results from its 2026 Annual Meeting of Stockholders held on May 20, 2026. |
| May 8, 2026 | debt_offering | Quest Diagnostics issued $500 million of 5.000% senior notes due 2036. |
| Jul 23, 2026 | Guidance: adjusted_diluted_eps | 11.05 to 11.25 |
| Jul 23, 2026 | Guidance: capital_expenditures | 550.00 to 550.00 |
| Jul 23, 2026 | Guidance: cash_provided_by_operations | 1800.00 to 1800.00 |
| Jul 23, 2026 | mda_quarterly | Quest Diagnostics reported strong second-quarter 2026 performance, with net revenues rising 10.2% to $3.04 billion, primarily driven by 10.0% organic growth. The Diagnostic Information Services (DIS) segment, which accounts for over 95% of revenue, saw a 13.1% increase in requisition volume. This volume surge was significantly bolstered by the new Corewell Health partnership and expanded testing at Fresenius Medical Care dialysis clinics. While volume grew, revenue per requisition declined 2.8%, reflecting a shift in business mix toward higher-volume, routine testing associated with these new relationships. To mitigate inflationary pressures and reimbursement challenges, the company continues its multi-year "Invigorate" program, targeting 3% annual cost savings through automation, artificial intelligence, and operational efficiencies. Capital allocation remains disciplined; the company issued $500 million in 2036 Senior Notes to refinance maturing debt and increased its quarterly dividend to $0.86 per share. Additionally, the board authorized a $1 billion share repurchase program, with $1.3 billion remaining as of June 30, 2026. Quest maintains a robust liquidity position with $1.3 billion in available credit capacity and expects to invest approximately $550 million in capital expenditures throughout 2026 to support laboratory infrastructure and the "Project Nova" business process modernization. |
| Apr 22, 2026 | mda_quarterly | Quest Diagnostics reported strong first-quarter 2026 results, with net revenues rising 9.2% to $2.895 billion. Growth was primarily driven by a 10.9% increase in diagnostic information services (DIS) volume, bolstered by the new Corewell Health partnership and expanded testing at Fresenius Medical Care dialysis clinics. While organic volume surged, revenue per requisition declined 1.3%, reflecting a shift in business mix toward routine testing associated with these new relationships. Operating income improved 15.5% to $399 million, benefiting from disciplined cost management. The company continues to execute its "Invigorate" program, which targets 3% annual cost savings through automation and AI to mitigate inflationary pressures, including rising labor and benefit costs. Strategic capital allocation remains a priority; the company declared a quarterly dividend of $0.86 per share and maintains $1.4 billion in share repurchase authorization. Financially, Quest remains well-positioned with $1.3 billion in available credit capacity and sufficient liquidity to fund operations, capital expenditures—estimated at $550 million for 2026—and debt obligations, including $500 million in senior notes maturing in June 2026. Management continues to focus on "Project Nova" to modernize order-to-cash processes and improve long-term operational efficiency. |
Source: SEC EDGAR filing text and events; period Jul 23, 2026; filed Jul 23, 2026.
DGX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.